Trial Profile
Safety and Immunologic Activity of Multiple Infusions of APN401
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs APN 401 (Primary)
- Indications Appendiceal cancer; Brain metastases; Colorectal cancer; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 18 Apr 2023 Results presented in an invIOs media release.
- 18 Apr 2023 According to an invIOs media release, company today announced data from a poster showing two patient case studies from this clinical trial of APN401 during the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
- 24 Nov 2021 Status changed from active, no longer recruiting to completed.